Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 10
Submit an article Journal homepage
102
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Aberrant expression of CD5 in adult acute myeloid leukemia belonged to AML-MR, may represent a uniquely aggressive subcategory

Yan ZhangDepartment of Hematology, The First Affiliated Hospital of China Medical University, Shenyang, ChinaORCID Iconhttps://orcid.org/0000-0001-6684-8985View further author information
ORCID Icon,
Yuanyi DingDepartment of Hematology, The First Affiliated Hospital of China Medical University, Shenyang, ChinaView further author information
,
Rui ZhangDepartment of Hematology, The First Affiliated Hospital of China Medical University, Shenyang, ChinaView further author information
,
Lijun ZhangDepartment of Hematology, The First Affiliated Hospital of China Medical University, Shenyang, ChinaView further author information
,
Xiaojing YanDepartment of Hematology, The First Affiliated Hospital of China Medical University, Shenyang, ChinaView further author information
&
Pingping WangDepartment of Hematology, The First Affiliated Hospital of China Medical University, Shenyang, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1900-623XView further author information
ORCID Icon
Pages 1711-1714 | Received 07 Nov 2023, Accepted 18 Mar 2023, Published online: 03 Jul 2023

References

  • Li X, Li J, Du W, et al. Relevance of immunophenotypes to prognostic subgroups of age, WBC, platelet count, and cytogenetics in de novo acute myeloid leukemia. APMIS. 2011;119(1):76–84. doi: 10.1111/j.1600-0463.2010.02694.x.
  • Khalidi HS, Medeiros LJ, Chang KL, et al. The immunophenotype of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and karyotypic abnormalities. Am J Clin Pathol. 1998;109(2):211–220. doi: 10.1093/ajcp/109.2.211.
  • Dunphy CH. Comprehensive review of adult acute myelogenous leukemia: cytomorphological, enzyme cytochemical, flow cytometric immunophenotypic, and cytogenetic findings. J Clin Lab Anal. 1999;13(1):19–26. doi: 10.1002/(SICI)1098-2825(1999)13:1<19::AID-JCLA4>3.0.CO;2-1.
  • Smith FO, Lampkin BC, Versteeg C, et al. Expression of lymphoid-associated cell surface antigens by childhood acute myeloid leukemia cells lacks prognostic significance. Blood. 1992;79(9):2415–2422. doi: 10.1182/blood.V79.9.2415.bloodjournal7992415.
  • Khoury JD, Solary E, Abla O, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–1719. doi: 10.1038/s41375-022-01613-1.
  • Meleshko AN, Movchan LV, Belevtsev MV, et al. Relative expression of different ikaros isoforms in childhood acute leukemia. Blood Cells Mol Dis. 2008;41(3):278–283. doi: 10.1016/j.bcmd.2008.06.006.
  • Launder TM, Bray RA, Stempora L, et al. Lymphoid-associated antigen expression by acute myeloid leukemia. Am J Clin Pathol. 1996;106(2):185–191. doi: 10.1093/ajcp/106.2.185.
  • Bhushan B, Chauhan PS, Saluja S, et al. Aberrant phenotypes in childhood and adult acute leukemia and its association with adverse prognostic factors and clinical outcome. Clin Exp Med. 2010;10(1):33–40. doi: 10.1007/s10238-009-0067-8.
  • Oelschlaegel U, Alexander Röhnert M, Mohr B, et al. Clonal architecture of del(5q) myelodysplastic syndromes: aberrant CD5 or CD7 expression within the myeloid progenitor compartment defines a subset with high clonal burden. Leukemia. 2016;30(2):517–520. doi: 10.1038/leu.2015.158.
  • Dannheim KC, Pozdnyakova O, Dal Cin P, et al. Immunophenotypic dysplasia and aberrant T-cell antigen expression in acute myeloid leukaemia with complex karyotype and TP53 mutations. J Clin Pathol. 2018;71(12):1051–1059. doi: 10.1136/jclinpath-2018-205348.
  • Lee KH, Lee JS, Suh CW, et al. Prognostic factors of acute myelocytic leukemia: an analysis of 132 patients in a single institution. J Korean Med Sci. 1996;11(3):222–232. doi: 10.3346/jkms.1996.11.3.222.
  • Lancet JE, Cortes JE, Hogge DE, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014;123(21):3239–3246. doi: 10.1182/blood-2013-12-540971.
  • Tallman MS, Wang ES, Altman JK, et al. Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(6):721–749. doi: 10.6004/jnccn.2019.0028.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.